论文部分内容阅读
Background Acute myeloid leukemia (AML) remains a challenging disease to treat in both pediatric and adult populations.Resistance to cytarabine (ara-C)and anthracycline [e.g., daunorubicin (DNR)]-based chemotherapy is a major cause of treatment failure in this disease.Therefore, more effective therapies are urgently needed to improve treatment outcome of AML patients.Chk1-selective inhibitor (LY2603618) and Bcl-2-selective inhibitor (ABT-199) have shown promising antitumor activities against AML.In this study, we sought to identify the molecular mechanisms underlying the anti-leukemic activities of LY2603618, and its synergistic anti-leukemic interaction with ABT-199 in AML cells.Methodology The anti-leukemic activities of LY2603618 and ABT-199 were determined by MTT assays.